Connect with us


Roche and Eurofins launch serological tests for COVID-19

Last month, NG Biotech announced the launch of a serological test to find if a person was infected with COVID-19. The latest announcements of developments of serological tests come from Roche laboratory and the Eurofins Technologies. The Elecsys Anti-SARS-CoV-2 test, developed by the Swiss laboratory, is an in vitro test based on a blood sample. The test is performed in 18 minutes.



This picture show some blood samples.

Serological tests detect the presence of antibodies specifically directed against the SARS-CoV-2 virus. After the PCR tests of bioMérieux or Abbott in particular, it is now the turn of serological tests to make their entry into the fight against COVID-19.

At the end of last month, NG Biotech announced the commercial launch of its rapid test. The COVID-19 NG-IgG-IgM Test is a serological strip test that simultaneously detects and differentiates the antibodies (IgM and/or IgG) produced by the body during the infection with the SARS-CoV-2 virus. The results are obtained in 15 minutes from a drop of blood.

CE marked on March 27th, following a first public order, this test was developed via a collaboration between biotech with AP-HP and CEA.

“The need for rapid tests being above all global production capacity, we will offer our tests as a priority to the French healthcare system, so that it can ensure better stratification of patients and monitoring of immune status as soon as possible,” said Milovan Stankov Pugès, the CEO of NG Biotech.

Consequently, the biotech company plans to open a second production site, in addition to that of Guipry located south of Rennes (Ille-et-Vilaine), in the short term to reach a production capacity of around two million of tests per month.

If you want to be the first to find the developments in the biotech sector and how companies from around the world are launching serological tests to identify if a person was infected with COVID-19, download the Born2Invest mobile app. Read the most important business headlines and stay on top of the market.

Roche and Eurofins the latest laboratories to launch serological tests

Latest announcements come from the Roche laboratory and the Eurofins Technologies. Each group has announced the development and launch of serological tests to identify people infected with the new coronavirus.

The Elecsys Anti-SARS-CoV-2 test, developed by the Swiss laboratory, is an in vitro test based on a blood sample and detects the presence of antibodies against SARS-CoV-2. The test can thus indicate whether a person has already been infected and has potentially developed immunity to the virus.

The test is performed in 18 minutes at a throughput of up to 300 tests per hour on Roche Cobas analyzers, which are already available in hospitals and reference laboratories around the world. The Swiss laboratory aims to make the test available at the beginning of May in countries accepting the CE mark, and is actively working with the FDA for emergency approval.

As a result, by June, Roche plans to accelerate production to manufacture up to one million tests per month. “Roche is working closely with health authorities and is accelerating production to ensure rapid global availability of the test,” said Severin Schwan, Roche CEO.

Eurofins Technology announced the launch of several CE marked serological in vitro diagnostic (IVD) medical devices for the detection of antibodies in patients who have been exposed to CoV-2 SARS.

Detecting the virus by the enzyme-linked immunosorbent assay (ELISA), the test has been developed with several Eurofins partners including Gold Standard Diagnostics and Virotech Diagnostics. For example, the test can be used as a complement to PCR tests to help diagnose the status and progression of acute infections.

“Our four factories and partners are preparing to produce kits for more than 10 million tests per month,” commented Gilles Martin, CEO of Eurofins.


(Featured image by Belova59 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in INDUSTRIEPharma, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Sharon Harris is a feminist and a part-time nomad. She reports about businesses primarily involved in tech, CBD, and crypto. She started her career as a product manager at a Silicon Valley startup but now enjoys a new life as a personal finance geek and writer. Her primary aim is to provide readers with a new perspective on the overlapping world of finance and technology.